Exosomes Archives | Page 24 of 27

Exosomics Siena Launches Exosome-Based Liquid Biopsy Solutions for Selective Analysis of Tumor-Derived DNA and RNA

July 23, 2018 By Cade Hildreth, Founder & President Leave a Comment

Lonza Pharma & Biotech backs Exosomics Siena S.p.A. as they launch first products for next-generation research and diagnostic applications.
Exosomics Siena’s technology to bring new, highly selective solutions for cancer detection, characterization and monitoring.

Siena (IT) and Basel (CH), 13 July 2018 – Exosomics Siena S.p.A., a pioneer and world leader in exosome-based diagnostics, today announced the launch of its first proprietary liquid biopsy solutions, SeleCTEV™ DNA and SortEV™ RNA, for the selective isolation of tumor-derived nucleic acids from complex biofluids such as plasma or serum. [Read more…]

Aegle Therapeutics Prepares Phase 1/2a Trial of BM-MSC Derived Extracellular Vesicles

July 20, 2018 By Cade Hildreth, Founder & President Leave a Comment

Aegle Therapeutics Corporation is the first extracellular vesicle (EV) company to be cleared by the FDA to enter clinical trials in humans. Headquartered in Miami, FL, the company is using allogeneic bone marrow mesenchymal stem cell (BM-MSC) derived extracellular vesicles to treat severe dermatological disorders, with a focus on burn treatments.

In May 2018, Aegle announced that the FDA cleared its first Investigational New Drug (IND) application to initiate a clinical trial in severe second degree burn patients. The company plans to launch a Phase 1/2a clinical trial of its lead product AGLE-102 in late 2018.

The open label dose escalation study will enroll patients at several sites in the U.S., evaluating the safety of extracellular vesicle therapy in burn patients. [Read more…]

Geographic “Hotspots” for Exosome Clinical Trials

July 10, 2018 By Cade Hildreth, Founder & President Leave a Comment

As exosomes become recognized for their benefits as cell-free therapeutics, exosome clinical trials are increasing in number. Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. They transfer DNA, RNA, and proteins to other cells, altering the function of target cells.

Exosome Clinical Trials

In addition to increasing in number, exosome clinical trials are tightly concentrated within specific regions of the world.

There are now 92 trials listed on ClinicalTrials.gov that contain the term “exosome” or “exosomes.” [Read more…]

Bio-Techne Acquires Exosome Diagnostics for $250M Cash Plus Milestones

July 8, 2018 By Cade Hildreth, Founder & President Leave a Comment

On June 25, 2018, Bio-Techne announced it is acquiring Exosome Diagnostics for $250 million in cash and up to $325 million for achieving certain milestones. As exosome therapeutics and diagnostics have multiplied in number, a number of investors have placed big bets on this rapidly growing marketplace.

Exosomes are small vesicles ranging from 30-100nm in size that are secreted by nearly all cell types. They facilitate a range of important cellular functions, including facilitating intercellular communication. [Read more…]

How Exosomes Are Revolutionizing Neuroimmunology with Dr. Stefano Pluchino

June 29, 2018 By Cade Hildreth, Founder & President Leave a Comment

Dr Stefano Pluchino - Pluchino Lab — Dr. Stefano Pluchino of the Pluchino Lab in Cambrige

I am honored to release this interview with Dr. Stefano Pluchino of the highly regarded Pluchino Lab in Cambridge, UK. Dr. Pluchino received his MD and PhD degrees at the University of Siena, Italy, and additional training at Cambridge University, UK.

Dr. Pluchino is an international expert on neuroimmunology-related applications of exosomes, with his lab exploring modalities by which neural progenitor cells (NPCs) engage in cell-to-cell communication. The focus of the laboratory is to explore cellular and molecular mechanisms regulating to the therapeutic plasticity of stem cells in preclinical models of CNS conditions, including multiple sclerosis (MS), stroke, and spinal cord injury. [Read more…]

Lonza Pharma & Biotech backs Exosomics Siena S.p.A. as they launch first products for next-generation research and diagnostic applications.

Exosomics Siena’s technology to bring new, highly selective solutions for cancer detection, characterization and monitoring.

Exosome Clinical Trials